meta|Evidence - COVID-19
Treament | Trials | |||||
---|---|---|---|---|---|---|
Demonstrated or suggested benefit | Inconclusive results | Uncertain results | Safety results | |||
|
14 | inconclusive results for: deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); death or ventilation; ventilation; serious adverse events; superinfection | - | - | ||
|
6 | demonstrated 32 % increase in clinical improvement suggested 49 % increase in clinical improvement (14-day) suggested 64 % increase in clinical improvement (28-day) suggested 29 % increase in clinical improvement (7-day) | inconclusive results for: deaths; deaths (time to event analysis only); clinical improvement (time to event analysis only); death or ventilation; ventilation; AE leading to drug discontinuation; deep vein thrombosis; hyperbilirubinemia; pulmonary embolism; renal impairment | - | - | |
|
35 | none | inconclusive results for: deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (time to event analysis only); death or ventilation; PCR-negative conversion; PCR-negative conversion (14-day); PCR-negative conversion (time to event analysis only); radiologic improvement (7-day); ventilation; ventilation (time to event analysis only); ICU admission; cardiac arrest; abnormal ECG findings; adverse events; arrhythmia | - | - | |
|
17 | inconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical improvement; clinical improvement (28-day); death or ventilation; PCR-negative conversion (7-day); ventilation; ICU admission; off oxygenation; serious adverse events | - | - | ||
|
8 | demonstrated 3.4-fold increase in clinical improvement (time to event analysis only) | inconclusive results for: deaths; clinical improvement; death or ventilation; hospital discharge; PCR-negative conversion (time to event analysis only); ventilation; ICU admission | - | - | |
|
18 | inconclusive results for: death or transfer to ICU; deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement (28-day); clinical improvement (time to event analysis only); hospital discharge; ventilation; ICU admission; superinfection | - | - | ||
|
6 | inconclusive results for: deaths; deaths (time to event analysis only); death or ventilation; ventilation; off oxygenation | - | - | ||
|
6 | inconclusive results for: death or transfer to ICU; deaths; clinical deterioration; clinical improvement; clinical improvement (28-day); clinical improvement (7-day); clinical improvement (time to event analysis only); hospital discharge; PCR-negative conversion; PCR-negative conversion (14-day); PCR-negative conversion (7-day); PCR-negative conversion (time to event analysis only); radiologic improvement (14-day); radiologic improvement (7-day); serious adverse events | - | - | ||
|
3 | none | inconclusive results for: deaths; clinical deterioration; ventilation | - | - | |
|
6 | inconclusive results for: deaths; death or ventilation; PCR-negative conversion | - | - | ||
|
1 | none | - | - | - |
Demonstrated: statistically demonstrated that is statistically significant with a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
![]() |
![]() |
![]() |
-
About
-
Our approach
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-